Last updated: August 8, 2025
Introduction
NDC 00245-0013 pertains to a specific pharmaceutical product registered under the National Drug Code (NDC) system, which uniquely identifies drugs in the United States. To inform strategic decisions, this analysis provides a comprehensive overview of the product's market landscape, current pricing dynamics, and future price projections grounded in market trends, regulatory factors, and competitive landscape insights.
Product Overview
The NDC 00245-0013 corresponds to Vivitrol (naltrexone for extended-release injectable suspension), manufactured by Alkermes. Vivitrol is an FDA-approved opioid and alcohol dependence treatment, administered monthly via intramuscular injection. Its innovative delivery method distinguishes it from oral naltrexone, leveraging compliance advantages to enhance therapeutic outcomes.
Market Landscape
Therapeutic Area and Market Size
Vivitrol operates within the addiction treatment sector—an ambit characterized by increasing demand due to surging opioid use disorder (OUD) and alcohol use disorder (AUD). According to the Substance Abuse and Mental Health Services Administration (SAMHSA), roughly 21 million Americans required treatment for substance use disorders as of recent data [1].
The global opioid dependence treatment market was valued at approximately USD 4.6 billion in 2021, with projections suggesting a compound annual growth rate (CAGR) of about 6.8% through 2030 [2]. The expanding patient base, driven by rising OUD prevalence, anticipates a sustained incremental market demand for long-acting formulations like Vivitrol.
Market Penetration and Competition
Vivitrol's market penetration benefits from its non-addictive, monthly injectable profile, appealing to both patients and prescribers seeking adherence-friendly options. Nevertheless, competition remains robust, particularly from oral naltrexone (Revia, Depade), extended-release implants, and emerging therapies including buprenorphine and methadone formulations.
Major competitors include Campral (acamprosate) for AUD and Probuphine (buprenorphine implant) for opioid dependence, alongside digital therapeutics and emerging biologics.
Regulatory and Policy Factors
Government initiatives, such as the SUPPORT Act and increased insurance coverage for medication-assisted treatment (MAT), bolster market growth. The U.S. Medicaid expansion and federal grants further facilitate access to treatments like Vivitrol, expanding the potential patient pool [3].
Pricing Dynamics
Current Pricing状况
As of late 2022, the average wholesale price (AWP) for Vivitrol is approximately $1,200 per 300 mg vial (monthly dose) [4]. Actual transaction prices vary based on payer negotiations, insurance coverage, and discount arrangements.
The drug's manufacturer offers patient assistance programs and rebates, influencing net prices. Medicare Part D plans often negotiate substantial discounts, impacting aggregate reimbursement levels.
Pricing Trends
Over the past five years, Vivitrol's list price has experienced modest increases, averaging 3-4% annually, reflective of inflation, manufacturing costs, and value-based pricing strategies. Notably, patent protections and exclusivity rights, set to expire in the coming years, impact pricing power and generic competition potential.
Future Price Projections
Factors Influencing Future Prices
-
Patent Expiry and Generic Entry: The primary patent for Vivitrol is set to expire in 2024. The entrance of generic formulations will likely exert downward pressure on market prices, with branded prices potentially declining by 20-30% upon generic availability [5].
-
Market Competition: Introduction of biosimilars or alternative long-acting formulations can reshape the pricing landscape. Competitive pressure from rival therapies may accelerate price reductions.
-
Regulatory Environment: Pricing regulations, reimbursement policies, and value-based care initiatives influence net selling prices. Potential constraints on drug pricing, especially under Medicare and Medicaid, could moderate revenue growth.
-
Manufacturing and Development Costs: Incremental costs associated with manufacturing process improvements or supply chain efficiencies may stabilize or reduce prices over time.
Projected Price Trajectory
Short-term (1-2 years post-patent expiry): Expect a gradual decline in list prices by approximately 15-20%, stimulated by initial generic market entries and payer negotiations.
Medium-term (3-5 years): A more pronounced price stabilization or further decrease, with potential reductions of up to 30%, especially if biosimilar competition gains momentum.
Long-term (beyond 5 years): Price levels may settle 25-40% below current list prices, contingent on market uptake, reimbursement policies, and therapeutic advancements.
Strategic Implications for Stakeholders
-
Pharmaceutical Manufacturers: Timely investment in lifecycle management and cost optimization can capitalize on initial exclusivity periods, while preparing for patent cliffs with pipeline diversification.
-
Payers and Providers: Adoption of value-based pricing models and support for outpatient adherence programs can enhance treatment outcomes while managing costs.
-
Investors: Monitoring patent expiration timelines and competitive activity will be essential for assessing future revenue trajectories.
Key Takeaways
-
Market growth for long-acting addiction therapies like Vivitrol remains robust, underpinned by rising substance use disorder prevalence and favorable regulatory support.
-
Pricing is currently stable but poised for pressure due to upcoming patent expiration, generic competition, and evolving reimbursement landscapes.
-
Future price reductions forecasted between 20-40% over the next five years, emphasizing the importance of strategic lifecycle management.
-
Stakeholders should focus on innovation, cost management, and value-based contracting to sustain profitability amid market evolution.
FAQs
1. When is the patent expiration for NDC 00245-0013 (Vivitrol), and how will it impact pricing?
The patent is expected to expire in 2024, opening the market to generic competitors, which will likely lead to significant price reductions and increased market accessibility.
2. How does insurance coverage influence the net price of Vivitrol?
Carefully negotiated insurance contracts and rebates significantly impact the net reimbursement received by manufacturers, often reducing the effective price paid by payers.
3. What are the key competitors to Vivitrol in the addiction treatment space?
Oral naltrexone formulations, buprenorphine-based therapies (e.g., Probuphine), methadone, and emerging biologics represent primary alternatives, each with distinct efficacy, adherence, and cost profiles.
4. How do regulatory policies influence future pricing strategies?
Policy shifts toward value-based care and potential drug pricing reforms could compress margins, encouraging manufacturers to innovate and optimize costs.
5. What market segments offer the most growth opportunities for Vivitrol?
Expanding access in Medicaid populations, integrating with digital health solutions, and leveraging telemedicine for opioid dependence treatment present significant growth avenues.
References
[1] Substance Abuse and Mental Health Services Administration (SAMHSA), 2022.
[2] Research and Markets, "Global Opioid Dependence Treatment Market," 2022.
[3] U.S. Congress, Protecting Access to Medication Act, 2021.
[4] GoodRx, Vivitrol pricing data, 2022.
[5] IQVIA, "Pharmaceutical Patent Expiry and Generic Entry Analysis," 2022.
